Companies: 10,795·Total market cap: $144.5T

Solid Biosciences Inc.

Solid Biosciences Inc.

SLDBNASDAQHealthcare● Active

$6.41

$-0.29(-4.33%)

Market Cap$499404382

P/E Ratio—

52W High$8.866

52W Low$3.79

Avg Volume1.3M

Open$6.84

Beta2.43

Net Income Financials Revenue

Solid Biosciences Inc. (SLDB) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

SLDB · net income · updated Jun 9, 2026

Core profitability metrics

SLDB · net income · margin · TTM · CAGR

Net income was −$174.3M for FY2025 (fiscal year ending 2025-12-31), down 39.8% year-over-year. Net profit margin was —.

FY2025 Net Income−$174.3M▼ -39.8% YoY

Trailing 12M (TTM)−$191.8Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change-39.8%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · SLDB net income history · SLDB profit margin

Annual net income data

SLDB · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$174.3M▼ 39.8%—$0

FY2024Loss−$124.7M▼ 29.9%—$0

FY2023Loss−$96.0M▼ 11.7%—$0

FY2022Loss−$86.0M▼ 19.1%-1062.3%$8.1M

FY2021Loss−$72.2M▲ +18.2%-530.0%$13.6M

Net income vs peers (Healthcare)

SLDB vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Solid Biosciences Inc.YOU

SLDB

−$174.3M-39.8%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Solid Biosciences Inc. (SLDB) reported net income of −$174.3M for FY2025 (fiscal year ending 2025-12-31), down 39.8% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Solid Biosciences Inc. has not yet achieved annual profitability based on available data (11 fiscal years). The company has reported net losses across all available periods.

Solid Biosciences Inc.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Solid Biosciences Inc. net worth" — the company's market capitalization is a separate figure from SLDB net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

SLDB net income · 4 questions

Solid Biosciences Inc. is not currently profitable on an annual basis. The company reported a net loss of $174.3M for FY2025.

is SLDB profitabledoes SLDB make a profitSLDB profitabilitySLDB profitable company

▸ Source: FMP /income-statement · GAAP · Solid Biosciences Inc. · Solid Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026